RxDoctor Payments Data

Asher Goldstein, MD

Pain Medicine · Hackensack, NJNPI 1790725661

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,914 of the $8,131 with a category attached, or 60.4%. 29 manufacturers reported payments, led by Relievant Medsystems, Inc. at 38.2% of the total. 2025 is the largest year on record at $3,232, 5.2 times the $625 reported in 2019.

$8,131in general payments, 2019–2025

Across 114 payments — averaging $71.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$3K
  • Saluda Medical Americas, Inc.$2K
  • Abbott$451
  • Medtronic$284
  • Curonix LLC$243
  • SPR Therapeutics, Inc$228
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$3,17839%
  • Food & beverage$4,91460%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,131 in reported general payments places this provider in the 85th percentile of 256 pain medicine providers in New Jersey.

See all pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$85,368
Medicare patients
124
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl22$15,213
Buprenorphine73$13,250
Xtampza ErOxycodone Myristate11$7,953
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen253$5,289
Oxycodone Hcl191$3,859
Gabapentin173$1,904
Fentanyl33$1,800
Naproxen77$1,433
Celecoxib43$1,410
Cyclobenzaprine Hcl59$1,106
Morphine Sulfate ErMorphine Sulfate12$763
Hydromorphone Hcl36$735
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen49$694
Duloxetine Hcl54$659
Tramadol Hcl57$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$23$7,95311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 pain medicine providers in New Jersey.

Other pain medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →